Bisphosphonates at therapeutic levels inhibit bone resorption and do not inhibit bone mineralization via binding to hydroxyapatite crystals. They impede osteoclast activity, and induce osteoclast apoptosis. Pamidronate has approximately 100 times greater relative antiresorptive potency when compared to etidronate. Bisphosphonates _in vitro_ have direct cytotoxic or cytostatic effects on human osteosarcoma cell lines. They may also have antiangiogenic effects and inhibit cell migration in certain cancers.
Pamidronate may be useful in treating hypercalcemia associated with vitamin D-related toxicoses or hypercalcemia of malignancy. There is ongoing research on the use of this drug to determine if it has clinical usefulness in directly treating “micro-metastases” in osteosarcomas.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
確認活性母體、二鈉鹽、水合狀態、完成品劑型、濃度、容器與標示表達一致。 逐案確認物種、病因、自發或誘發疾病、腎臟狀況、水合狀態、鈣磷鎂鉀與維生素狀態、口腔牙科風險、併用治療與追蹤能力。 由主治獸醫師建立產品特定的調製、相容性、給藥、監測、停止與救援計畫；本審查不得直接驅動處方或計算器。 所有互動作用須完成雙向、雙語、物種與產品特定的嚴重度及處置契約；目前全部維持未評估且封閉。
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。